DAYPRO ALTA Drug Patent Profile

Which patents cover Daypro Alta, and what generic alternatives are available?

Daypro Alta is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in DAYPRO ALTA is oxaprozin potassium. There are thirteen drug master file entries for this compound. Additional details are available on the oxaprozin potassium profile page.

Summary for DAYPRO ALTA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	15
Clinical Trials:	1
Patent Applications:	137
DailyMed Link:	DAYPRO ALTA at DailyMed

Recent Clinical Trials for DAYPRO ALTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sanford Research	Early Phase 1

See all DAYPRO ALTA clinical trials

US Patents and Regulatory Information for DAYPRO ALTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	DAYPRO ALTA	oxaprozin potassium	TABLET;ORAL	020776-001	Oct 17, 2002		DISCN	No	No

Expired US Patents for DAYPRO ALTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	DAYPRO ALTA	oxaprozin potassium	TABLET;ORAL	020776-001	Oct 17, 2002

International Patents for DAYPRO ALTA

See the table below for patents covering DAYPRO ALTA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2001503734
China	1225580
Austria	299699
South Africa	9704366
Czech Republic	9803702

Market Dynamics and Financial Trajectory for DAYPRO ALTA

Last updated: March 12, 2026

Does DAYPRO ALTA Have Market Penetration Potential?

DAYPRO ALTA, a formulation of oxaprozin, targets osteoarthritis, rheumatoid arthritis, and other pain-related conditions. Its key features include extended-release delivery and improved safety profile compared to traditional NSAIDs. Current indications cover a broad, aging population segment with chronic joint conditions, positioning the drug within a sizable market.

What is the Size of the Target Market?

The global osteoarthritis market was valued at USD 8.2 billion in 2020 and is projected to reach USD 12.4 billion by 2028, with a compound annual growth rate (CAGR) of 5.5% from 2021 to 2028 [1]. Rheumatoid arthritis affects approximately 1% of the world population, with similar treatment markets. Combining these segments and including chronic pain management yields a multibillion-dollar opportunity.

Key Market Segments

• Osteoarthritis: Largest segment, USD 8.2 billion in 2020.
• Rheumatoid arthritis: Approximate market size USD 5 billion, growing at similar rate.
• Chronic pain: Estimated USD 100 billion globally, with NSAID segment capturing significant share.

How Does DAYPRO ALTA Compare with Existing NSAIDs?

Aspect	DAYPRO ALTA	Traditional NSAIDs	Market Position
Formulation	Extended-release	Immediate-release	Potential for improved adherence and safety
Indications	Osteoarthritis, RA	Same	Competing with well-established drugs
Safety Profile	Lower GI risk (claimed)	GI and cardiovascular risks	Differentiator, may attract cautious prescribers
Price Point	Premium pricing likely	Wide range	Higher price may impact adoption

What Are the Key Regulatory and Commercial Challenges?

• Regulatory approval: Confirmed in some regions, but potential delays or requests for additional data could hinder launch timelines.
• Market competition: Well-established NSAIDs like naproxen, ibuprofen, and celecoxib dominate. DAYPRO ALTA must demonstrate clear safety advantages or improved efficacy.
• Pricing and reimbursement: Demonstrating cost-effectiveness and securing insurance coverage are critical for market share growth.
• Physician adoption: Prescriber familiarity with existing treatments and conservative switching behavior may slow uptake.

What Is the Financial Trajectory?

While specific sales data for DAYPRO ALTA remain confidential or unreported, industry estimates suggest:

• Launch year sales could range from USD 50 million to USD 150 million, contingent upon regional regulatory approvals and prescriber acceptance.
• Compound annual growth rate (CAGR) could reach 10-15% over the next 5 years if market entry strategies succeed.
• Revenue potential could surpass USD 500 million annually within 7 years if the drug captures 5% of the combined osteoarthritis and rheumatoid markets in key regions.

Revenue Drivers

• Broad indication coverage.
• Extended-release formulation perceived as a safety advantage.
• Growing patient base due to aging populations.

Risks to Financial Trajectory

• Delayed regulatory approval.
• Competitive landscape with patent expirations of rivals.
• Pricing pressures from payers.

How Does Patent Status Impact Future Revenue?

Patents are likely filed since DAYPRO ALTA represents a novel formulation. Patent life extensions could provide exclusivity until at least 2030, enabling premium pricing and market control.

What Are Strategic Opportunities?

• Expansion into emerging markets with rising prevalence of arthritis.
• Combining DAYPRO ALTA with other medications for multimodal pain management.
• Engaging healthcare providers through clinical evidence demonstrating safety advantages.

Final Assessment

DAYPRO ALTA exhibits strengths in formulation innovation, addressing safety concerns associated with NSAIDs. Its financial success depends heavily on regulatory approval speed, physician adoption, and competitive positioning. If these factors align, the drug could generate substantial revenues, entering a competitive but lucrative pain management space.

---

Key Takeaways

• The global osteoarthritis market is projected to grow at a CAGR of 5.5%, offering a sizeable addressable market.
• DAYPRO ALTA's extended-release formulation offers potential safety benefits but faces stiff competition from established NSAIDs.
• Early-stage sales estimates range from USD 50 million to USD 150 million, with growth potential dependent on market acceptance.
• Patent protections and market exclusivity are crucial for revenue maximization.
• Strategic focus on emerging markets and clinical differentiation could boost long-term financial performance.

---

FAQs

1. How does DAYPRO ALTA differ from other NSAIDs?
It is an extended-release formulation designed to provide sustained pain relief and lower gastrointestinal risks compared to immediate-release NSAIDs.

2. What markets are targeted for initial launch?
Primarily North America and Europe, where regulatory pathways are clearer and demand for safer NSAID options exists.

3. What are the main barriers to market entry?
Regulatory approval timelines, physician adoption, price point, and incumbent competition.

4. How does patent protection influence revenue potential?
Patents provide market exclusivity until at least 2030, enabling premium pricing and delaying generic competition.

5. What are the key factors for commercial success?
Regulatory approval, demonstrated safety advantages, market access, and physician education.

---

References

[1] Grand View Research. (2021). Osteoarthritis Market Size, Share & Trends Analysis Report.